Fig. 3From: Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancerThe developed nomogram for predicting overall survival. The nomogram was developed based on the training cohort, with the use of pleural metastasis, neutrophils, lymphocytes, B cells and TregsBack to article page